MENU
+Compare
FMED
ETF ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$25.69
Change
-$0.41 (-1.57%)
Net Assets
55.48M

FMED stock forecast, quote, news & analysis

Category: @Health
FMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for FMED with price predictions
Feb 20, 2025

FMED sees its Stochastic Oscillator ascends from oversold territory

On February 14, 2025, the Stochastic Oscillator for FMED moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 21 instances where the indicator left the oversold zone. In of the 21 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

FMED moved above its 50-day moving average on January 21, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for FMED crossed bullishly above the 50-day moving average on January 23, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 4 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FMED advanced for three days, in of 100 cases, the price rose further within the following month. The odds of a continued upward trend are .

FMED may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 72 cases where FMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for FMED moved out of overbought territory on January 31, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 similar instances where the indicator moved out of overbought territory. In of the 9 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on February 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on FMED as a result. In of 29 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FMED turned negative on February 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 16 similar instances when the indicator turned negative. In of the 16 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMED declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Regeneron Pharmaceuticals (NASDAQ:REGN), Edwards Lifesciences Corp (NYSE:EW), Humana (NYSE:HUM), Centene Corp (NYSE:CNC), Align Technology (NASDAQ:ALGN).

Industry description

The investment seeks long-term growth of capital. The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.

Market Cap

The average market capitalization across the Fidelity Disruptive Medicine ETF ETF is 51.65B. The market cap for tickers in the group ranges from 59.07M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is ALXO at 59.07M.

High and low price notable news

The average weekly price growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was 16%. For the same ETF, the average monthly price growth was 29%, and the average quarterly price growth was 98%. NTLA experienced the highest price growth at 27%, while UNH experienced the biggest fall at -5%.

Volume

The average weekly volume growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was -5%. For the same stocks of the ETF, the average monthly volume growth was -5% and the average quarterly volume growth was 66%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 62
P/E Growth Rating: 66
Price Growth Rating: 54
SMR Rating: 78
Profit Risk Rating: 72
Seasonality Score: -61 (-100 ... +100)
View a ticker or compare two or three
FMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
82 Devonshire StreetBoston
Phone
N/A
Web
www.institutional.fidelity.com